Healthcare -
Biotechnology - NASDAQ - US
$ 11.8
2.79 %
$ 1.79 B
Market Cap
-12.42
P/E
1. INTRINSIC VALUE
Balance Sheet
Adaptive Biotechnologies Corporation
| Current Assets | 284 M |
| Cash & Short-Term Investments | 222 M |
| Receivables | 41.7 M |
| Other Current Assets | 19.7 M |
| Non-Current Assets | 256 M |
| Long-Term Investments | 33.7 M |
| PP&E | 94.4 M |
| Other Non-Current Assets | 128 M |
| Current Liabilities | 98.1 M |
| Accounts Payable | 7.26 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 90.8 M |
| Non-Current Liabilities | 239 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 239 M |
EFFICIENCY
Earnings Waterfall
Adaptive Biotechnologies Corporation
| Revenue | 179 M |
| Cost Of Revenue | 72.1 M |
| Gross Profit | 107 M |
| Operating Expenses | 269 M |
| Operating Income | -163 M |
| Other Expenses | -2.95 M |
| Net Income | -160 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Adaptive Biotechnologies Corporation
| Net Income | -160 M |
| Depreciation & Amortization | 19.3 M |
| Capital Expenditures | -3.66 M |
| Stock-Based Compensation | 53.6 M |
| Change in Working Capital | -17.5 M |
| Others | -7.35 M |
| Free Cash Flow | -98.9 M |
Wall Street Analysts Price Targets
Adaptive Biotechnologies Corporation
Wall Street analysts predict an average 1-year price target for ADPT of $11.3 , with forecasts ranging from
a
low of
$5 to a high of $18 .
ADPT Lowest Price Target
Wall Street Target
5 USD
-57.63%
ADPT Average Price Target
Wall Street Target
11.3 USD
-4.24%
ADPT Highest Price Target
Wall Street Target
18 USD
52.54%
4. DIVIDEND
ANALYSIS
ADPT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Adaptive Biotechnologies Corporation
Sold
0-3 MONTHS
537 K USD 2
3-6 MONTHS
10.7 M USD 10
6-9 MONTHS
1.24 K USD 1
9-12 MONTHS
121 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
zacks.com
- 3 days ago
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
clonoSEQ® is now integrated into Flatiron Health's OncoEMR®, simplifying MRD testing access for over 4,500 clinicians across the Flatiron network.
globenewswire.com
- 6 days ago
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
zacks.com
- 1 week ago
What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 3 weeks ago
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
zacks.com
- 3 weeks ago
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
globenewswire.com
- 1 month ago
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL.
globenewswire.com
- 1 month ago
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
- 1 month ago
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
- 1 month ago
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chief Executive Officer & Co-Founder Kyle Piskel - Chief Financial Officer Susan Bobulsky - Chief Commercial Officer Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Yuko Oku - Morgan Stanley Sebastian Sandler - JPMorgan Tom Stevens - TD Cowen Corey Rosenbaum - Scotia Bank Maggie Boeye - William Blair Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter 2025 Earnings Conference Call.
seekingalpha.com
- 2 months ago
8. Profile
Summary
Adaptive Biotechnologies Corporation ADPT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.79 B
Dividend Yield
0.00%
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Contact
1165 Eastlake Avenue East, Seattle, WA, 98109
https://www.adaptivebiotech.com
IPO
Date
June 27, 2019
Employees
619
Officers
Dr. Harlan S. Robins Ph.D.
Co-Founder & Chief Scientific Officer
Mr. Francis T. Lo
Chief People Officer
Ms. Julie Rubinstein
President & Chief Operating Officer
Mr. Kyle Piskel
Vice President, Chief Financial Officer & Principal Accounting Officer
Dr. Sharon Benzeno Ph.D.
Chief Commercial Officer of Immune Medicine
Mr. Christopher Carlson Ph.D.
Founder
Ms. Karina Calzadilla
Vice President of Investor Relations
Ms. Susan Bobulsky
Chief Commercial Officer of MRD
Mr. Chad M. Robins M.B.A.
Co-Founder, Chief Executive Officer & Chairman
Ms. Clarice McCauley
Interim General Counsel, Corporate Secretary, Vice President & Chief Compliance Officer